MPL Pharma SRL
1.6 FTEThe score of MPL Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2023 → 2026: Equity -4 % Total assets -15 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 11 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
MPL Pharma's annual accounts
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net result | 111,202 € | ||||
| Equity | 724,397 € | ||||
| Cash | 336,008 € | ||||
| EBITDA | 250,592 € | ||||
| Total assets | €1.05m |
Filed annual accounts
- Year ended 31 Mar 2026filed on 29 Oct 2026
- Year ended 31 Mar 2025filed on 31 Oct 2025
- Year ended 31 Mar 2024filed on 31 Oct 2024
- Year ended 31 Mar 2023filed on 30 Nov 2023
- Year ended 31 Mar 2022filed on 03 Oct 2022
MPL Pharma's financial analysis
- Solvency68.8%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of MPL Pharma
MPL Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0885.177.557
- VAT number
- BE0885177557
- Peppol
- Registered · 0208:0885177557 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Nov 2006
- Registered office
- 5590 Ciney
- Size
- Micro · 1.6 FTE
- Latest accounts
- 2026 · filed on 29 Oct 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
MPL Pharma (SRL) has been based in Ciney since 2006, active in: retail sale of pharmaceutical products. For 2026, it reports a net profit of 111,202 € and equity of 724,397 €; its revenue is not published. With 1.6 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 68.8%, above the median of its sector (41.5%).
Companies similar to MPL Pharma
Companies in the same business, of comparable size and area, outside its group.
- A.S. Farma Retail sale of pharmaceutical products Antwerp · balance sheet €1.05m
- Apotheek ST-Joris Retail sale of pharmaceutical products Tielt-Winge · balance sheet €1.05m
- Findiap Retail sale of pharmaceutical products Zonnebeke · balance sheet €1.06m
- Pharmacie Bolly A Saint-Georges Retail sale of pharmaceutical products Saint-Georges-sur-Meuse · balance sheet €1.05m
- Apoteek Roggen Retail sale of pharmaceutical products Dilbeek · balance sheet €1.05m
- Aerts Pharma Retail sale of pharmaceutical products Zonhoven · balance sheet €1.04m
- Farmacenter Retail sale of pharmaceutical products Overijse · balance sheet €1.04m
- A-Cura Retail sale of pharmaceutical products Beringen · balance sheet €1.04m
Frequently asked questions about MPL Pharma
What is the revenue of MPL Pharma?
MPL Pharma files its accounts in a format where revenue is optional: it is not published for 2026.
What is the VAT number of MPL Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0885177557 for MPL Pharma, if the company is VAT-registered. Its company number (CBE) is 0885.177.557.
Where is the registered office of MPL Pharma?
According to the CBE register, the registered office of MPL Pharma is in 5590 Ciney.
What is the equity of MPL Pharma?
At the close of the 2026 financial year, the equity of MPL Pharma amounts to 724,397 €, a solvency of 68.8% of total assets.
How many people work at MPL Pharma?
1.6 full-time equivalents on average according to the 2026 social balance sheet.
Who manages MPL Pharma?
The register lists 1 active mandates at MPL Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of MPL Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →